[Congressional Record Volume 157, Number 91 (Thursday, June 23, 2011)]
[Extensions of Remarks]
[Pages E1172-E1173]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                      HONORING RACHEL ANSZELOWICZ

                                  _____
                                 

                           HON. STEVE ISRAEL

                              of new york

                    in the house of representatives

                        Thursday, June 23, 2011

  Mr. ISRAEL. Mr. Speaker, I rise today to commend an extraordinary 
constituent of mine, Rachel Anszelowicz.
  Rachel visited my office recently to tell me about how difficult it 
is to live with type 1 diabetes. She told me about the painful glucose 
monitors and burdensome insulin pumps that she and other children with 
juvenile diabetes use to manage their disease. And, she told me about 
her increased risk as an adult for, among other ailments, kidney 
failure and heart disease. As a 2011 Children's Congress delegate from 
the Juvenile Diabetes Research Foundation, Rachel spoke with a poise 
and maturity beyond her 13 years.
  In her fight with the disease, Rachel is not alone. As many as 
twenty-six million Americans have diabetes, which ultimately accounts 
for $174 billion in health care costs in the United States, and twenty-
two percent of hospital inpatient days. If we are to bring down this 
country's rising health care costs, then new cost effective and high 
quality treatments for chronic diseases like diabetes will be a 
critical part of that effort.
  Research by the Juvenile Diabetes Research Foundation and other 
clinical experts

[[Page E1173]]

has indicated that an artificial pancreas could be a potentially 
transformative tool to manage type 1 diabetes. By automatically 
controlling blood glucose levels, it would drastically improve the 
quality of life for those like Rachel Anszelowicz who struggle daily 
with the disease.
  There is currently no ``quick-fix'' or lasting solution for type 1 
diabetes. There is no cure. So, for Rachel and my other constituents 
with juvenile diabetes, I will continue to support the research 
necessary to translate these and other innovations from lab tested to 
in daily use by patients.

                          ____________________